NCT04203485

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

A Randomized, Open-Label, Controlled, Multicenter Phase III Study of Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone Versus Platinum-based Chemotherapy for First-line Treatment in Subjects With PD-L1 Positive Relapsed or Advanced NSCLC

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 762 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.

Conditions

• PD-L1 Positive Non-small Cell Lung Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Camrelizumab 200mg	Camrelizumab 200mg q2w ivgtt
DRUG	Apatinib Mesylate 250mg	Apatinib Mesylate 250mg po qd
DRUG	Pemetrexed disodium for injection	Pemetrexed disodium for injection 500 mg/m2 q3w
DRUG	Paclitaxel injection	Paclitaxel injection 175 mg/m2 q3w
DRUG	Carboplatin	Carboplatin AUC 5 mg/mL/min q3w

Timeline

• Start date: 2020-06-15
• Primary completion: 2022-03-31
• Completion: 2022-05-31
• First posted: 2019-12-18
• Last updated: 2020-05-08